Alejandra Ugarte-Torres1, Mark R Gillrie2, Thomas P Griener3, Deirdre L Church4. 1. Department of Medicine, Division of Infectious Diseases, Alberta Health Services, University of Calgary, Alberta, Canada. 2. Department of Microbiology, Immunology and Infectious Diseases, Alberta, Canada. 3. Department of Pathology & Laboratory Medicine, Cumming School of Medicine, University of Calgary, Alberta, Canada. 4. Department of Medicine, Division of Infectious Diseases, Department of Pathology & Laboratory Medicine and Medicine, University of Calgary, Section of Microbiology, Calgary Laboratory Services, Alberta, Canada.
Abstract
Background: Eggerthella lenta is a anaerobic gram-positive bacilli associated with polymicrobial intraabdominal infections. Recently, E. lenta was recognized as an important cause of anaerobic bloodstream infections (BSIs) associated with high mortality. Eggerthella lenta has been reported to have high minimal inhibitory concentrations (MICs) to piperacillin-tazobactam (TZP), a broad-spectrum antibiotic with anaerobic coverage commonly used in multiple centers for empiric treatment of abdominal sepsis. Methods: We describe a retrospective population-based analysis of invasive E. lenta infections from 2009 through 2015. A logistic regression analysis for 30-day mortality risk factors was conducted. Results: We identified 107 E. lenta infections, 95 (89%) were BSIs, 11 (10%) skin and soft tissue infections, and 1 intraabdominal abscess. Polymicrobial infections were found in 40%; 72% of isolates were from a gastrointestinal source, most commonly appendicitis (33%) of which two-thirds were perforated. TZP MIC50 and MIC90 for E. lenta isolates were 32 μg/mL and 64 μg/mL, respectively. The overall 30-day mortality for BSI was 23% and was independently associated with empiric TZP monotherapy (odds ratio [OR], 4.4; 95% confidence interval [CI], 1.2-16; P = .02) and intensive care unit stay (OR, 6.2; 95% CI, 1.4-27.3; P = .01). Thirty-day mortality rates were significantly influenced by the use of different TZP MIC breakpoints. Conclusions: Our results demonstrate the increased recognition of E. lenta as an anaerobic opportunistic pathogen and highlight the need for improved empiric antimicrobial guidelines and TZP MIC breakpoints with better correlation to clinical outcomes to guide appropriate management of invasive E. lenta infections.
Background: Eggerthella lenta is a anaerobic gram-positive bacilli associated with polymicrobial intraabdominal infections. Recently, E. lenta was recognized as an important cause of anaerobic bloodstream infections (BSIs) associated with high mortality. Eggerthella lenta has been reported to have high minimal inhibitory concentrations (MICs) to piperacillin-tazobactam (TZP), a broad-spectrum antibiotic with anaerobic coverage commonly used in multiple centers for empiric treatment of abdominal sepsis. Methods: We describe a retrospective population-based analysis of invasive E. lenta infections from 2009 through 2015. A logistic regression analysis for 30-day mortality risk factors was conducted. Results: We identified 107 E. lenta infections, 95 (89%) were BSIs, 11 (10%) skin and soft tissue infections, and 1 intraabdominal abscess. Polymicrobial infections were found in 40%; 72% of isolates were from a gastrointestinal source, most commonly appendicitis (33%) of which two-thirds were perforated. TZP MIC50 and MIC90 for E. lenta isolates were 32 μg/mL and 64 μg/mL, respectively. The overall 30-day mortality for BSI was 23% and was independently associated with empiric TZP monotherapy (odds ratio [OR], 4.4; 95% confidence interval [CI], 1.2-16; P = .02) and intensive care unit stay (OR, 6.2; 95% CI, 1.4-27.3; P = .01). Thirty-day mortality rates were significantly influenced by the use of different TZP MIC breakpoints. Conclusions: Our results demonstrate the increased recognition of E. lenta as an anaerobic opportunistic pathogen and highlight the need for improved empiric antimicrobial guidelines and TZP MIC breakpoints with better correlation to clinical outcomes to guide appropriate management of invasive E. lenta infections.
Authors: Deirdre L Church; Lorenzo Cerutti; Antoine Gürtler; Thomas Griener; Adrian Zelazny; Stefan Emler Journal: Clin Microbiol Rev Date: 2020-09-09 Impact factor: 26.132
Authors: Heleen Aardema; Paola Lisotto; Alexander Kurilshikov; Janneke R J Diepeveen; Alex W Friedrich; Bhanu Sinha; Anne Marie G A de Smet; Hermie J M Harmsen Journal: Front Cell Infect Microbiol Date: 2020-01-15 Impact factor: 5.293
Authors: Aasia Khaliq; Resmi Ravindran; Samia Afzal; Prasant Kumar Jena; Muhammad Waheed Akhtar; Atiqa Ambreen; Yu-Jui Yvonne Wan; Kauser Abdulla Malik; Muhammad Irfan; Imran H Khan Journal: PLoS One Date: 2021-01-22 Impact factor: 3.240